ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas

Brief description of study

If you or your child has been diagnosed with high grade gliomas (a type of brain cancer), you or your child may qualify to participate in a study evaluating the safety and effectiveness of an investigational drug known as ONC201. The goal of this phase I study is to find out the safety and effectiveness of an experimental drug known as ONC201 for the treatment of high grade gliomas.

Clinical Study Identifier: s17-01601
ClinicalTrials.gov Identifier: NCT03416530
Principal Investigator: Sharon L Gardner.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.